SOUTH KOREA · OPENDART
KYONGBO PHARMACEUTICAL CO., LTD.
경보제약 · 214390 · KOSPI · Healthcare · Drug Manufacturers—Specialty & Generic
Score
Not ranked: no net buying on the exchange by an individual insider in the last 180 days.
Insiders' buying price vs the latest close
Insiders paid 5,842.22 KRW a share on average (5 purchase lines, 3 buyers, 2025-11-18 – 2026-03-13). The close on 2026-10-16 was 10.1% below that price.
The latest purchase (2026-03-13) was at 5,535.00 KRW; the close was 5.1% below that price.
Prices paid are weighted by shares and taken from the filings; dividends are not counted. Not scored.
Insider trades on the exchange
Purchases and sales on the exchange in the last 12 months. The filing gives the settlement date; the trade date is two trading days earlier.
| Trade date | Insider | Role | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-03-13 | Hong Sung Sang | Managing director | Bought on the exchange | 2,000 | ₩5,535 | ₩11.1M | DART ↗ |
| 2026-03-03 | Jung Hee Rok | Director | Bought on the exchange | 200 | ₩5,730 | ₩1.1M | DART ↗ |
| 2026-02-24 | Hong Sung Sang | Managing director | Bought on the exchange | 3,000 | ₩5,996 | ₩18.0M | DART ↗ |
| 2026-02-05 | Kim Do Kyoung | Auditor | Bought on the exchange | 1,000 | ₩5,880 | ₩5.9M | DART ↗ |
| 2025-11-18 | Kim Do Kyoung | Auditor | Bought on the exchange | 1,000 | ₩5,980 | ₩6.0M | DART ↗ |
Other changes in holdings · 2
Option exercises, grants, new shares, inheritance, gifts, off-exchange trades and trades by companies and funds. Not counted in the score.